Company profile for Aveo Oncology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and...
AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
One Broadway, 14th Floor Cambridge, MA 02142
Telephone
Telephone
617-588-1960
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/aveo-oncology-an-lg-chem-company-and-hibercell-enter-into-an-exclusive-development-and-option-agreement-for-first-in-human-compound-302603732.html

PR NEWSWIRE
04 Nov 2025

https://www.prnewswire.com/news-releases/aveo-oncology-an-lg-chem-company-presents-three-posters-at-asco-2025-annual-meeting-302471712.html

PR NEWSWIRE
03 Jun 2025

https://www.prnewswire.com/news-releases/aveo-oncology-an-lg-chem-company-announces-three-poster-presentations-at-asco-2025-annual-meeting-302438792.html

PR NEWSWIRE
28 Apr 2025

https://www.prnewswire.com/news-releases/aveo-oncology-an-lg-chem-company-presents-two-posters-for-tivozanib-at-the-2025-asco-gu-meeting-302377714.html

PR NEWSWIRE
18 Feb 2025

https://www.prnewswire.com/news-releases/aveo-oncology-an-lg-chem-company-announces-tivozanib-presentations-at-asco-gu-2025-302374155.html

PR NEWSWIRE
12 Feb 2025

https://www.prnewswire.com/news-releases/aveo-oncology-an-lg-chem-company-present-tinivo-2-results-and-tivo-3-exploratory-post-immunotherapy-survival-analysis-at-esmo-2024-302248624.html

PR NEWSWIRE
16 Sep 2024

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty